Buy & Sell Eaton Corporation plc (ETN) – Eaton Corporation plc Price Today
Aura AI Summary
Key Stats
- $152.85BMarket Cap
- TechnologySector
- -14.12%3M Drawdown
- $173.93BEnterprise Value
- 1.12%Dividend Yield
- 85% Buy | 15% SellTrading Activity
- 12 daysTypical Hold Time
Eaton Corporation plc (ETN) is currently valued at a market capitalization of $152.85B, with an enterprise value of $173.93B. Over the past 52 weeks, Eaton Corporation plc has traded between a low of $315.82 and a high of $433.01, highlighting its annual price range. Over the past three months, Eaton Corporation plc has recorded a drawdown of -14.12%, reflecting recent price volatility. Eaton Corporation plc offers a dividend yield of 1.12%, with the most recent dividend of $1.10 paid on 08 May 26. On average, investors hold Eaton Corporation plc for approximately 12 days, indicating typical investor behavior on the platform.
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Most Recent News
US government buys 10% stake in mining firms, signaling a new strategic investment trend.
In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...

FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...

FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.
The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...
